# AFP- L3% and DCP as Tumor Markers in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Chemoembolisation (TACE)

> **NCT01360255** · — · COMPLETED · sponsor: **University Hospital Freiburg** · enrollment: 70 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01360255
- **Lead sponsor:** University Hospital Freiburg
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2015-11
- **Final completion:** 2015-11-15
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2018-10-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01360255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01360255, "AFP- L3% and DCP as Tumor Markers in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Chemoembolisation (TACE)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01360255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*